Shankar Siva· @_ShankarSiva · X·· 1 天前评分70
正文 · 原文
#ESMO26 @tompowles1 presents at the 👑presidential 👑 session VOLGA n=1009 phIII neoadjuvant #bladdercancer trial. 24mo EFS 63.5% vs 45% (HR 0.51), pCR 45% vs 10%. Triplet +tremelimumab hits EFS but not yet OS. #MIBC - @NEJM paper ➡️ ➡️ https://shorturl.at/7cyc9
146 浏览 · 2 赞 · 2 转发 · 0 回复
会议摘要
LBA2按 Presidential Symposium I 对上
Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgVOLGA
https://esmocongress.esmo.org来源：Shankar Siva · x.com